Front Line COVID-19 Critical Care Alliance (FLCCC)
One Sentence Summary Review of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19.
Ivermectin https://bnf.nice.org.uk/drug/ivermect… Invitro antiviral activity Against a broad range of viruses HIV, dengue, influenza, Zika virus Invitro antiviral, SARS-CoV-2 activity 99.8% reduction in viral RNA after 48 h Worldwide use for treating COVID-19 A
Preexposure prophylaxis in high-risk patients Postexposure prophylaxis Symptomatic patients at home Mildly symptomatic patients in hospital Progressive Respiratory symptoms Ivermectin has emerged as the “wonder drug” to prophylaxis and treat COVID-19 Ivermectin inhibits viral replication and has potent anti-inflammatory properties
There is the potential for serious drug-drug interaction Additional, studies are urgently required to confirm these very impressive preliminary findings Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (7th December) https://covid19criticalcare.com/wp-co…
Front Line COVID-19 Critical Care Alliance (FLCCC) One Sentence Summary Review of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The ICON Study (October 2020, South Florida) https://www.ncbi.nlm.nih.gov/pmc/arti…
Research Question Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients? Study Design and Methods Consecutive patients hospitalized Four hospitals in Florida Confirmed COVID-19 March 15 and May 11, 2020 Treated with or without ivermectin Primary outcome All-cause in-hospital mortality Secondary outcomes, mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, length of stay Severe pulmonary involvement Need for Fio2 ≥ 50%, noninvasive ventilation Invasive ventilation Results from reviews N = 280 Ivermectin treated = 173 Overall mortality 15% Mortality with severe pulmonary involvement = 38.8% Not given ivermectin = 107 Overall mortality 25% (OR, 0.52) Mortality with severe pulmonary involvement = 80.7%
No significant differences were found in extubation rates or length of stay Most patients in both groups also received hydroxychloroquine, azithromycin, or both Interpretation Ivermectin treatment was associated with lower mortality during treatment of COVID-19 Especially in patients with severe pulmonary involvement Randomized controlled trials are needed to confirm these findings